retatrutide clinical trials Results: 28.3% Weight Loss Data Lilly's triple agonist, retatrutide, delivered
Description
Tanaka T, Camerini D, Seed B, Torimoto Y, Dang NH, Kameoka J, et al
Were here to support you every step of the way.
This allows your provider to determine whether GLP-1 therapy may be appropriate based on your individual goals and medical profile
So that's pretty cool
Shima Hadidchi, MD, who can provide tailored treatment plans to suit your specific health goals
